On account of the growing number of diabetic patients, increasing geriatric population, technological advancements in insulin delivery devices, and rising population exposed to risk factors are leading to the growth of the human insulin market. The global market generated a revenue of $42.9 billion in 2017, and it is expected to witness a CAGR of 8.8% during the forecast period (2018–2023). Human insulin (HI) is synthetic insulin, which mimics the effects and functionality of natural insulin in humans. It is generally created by growing the insulin protein in the E. coli bacteria.

Download Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/human-insulin-market/report-sample

Similarly, the application segment of the human insulin market consists of type 1 diabetes, type 2 diabetes, and gestational diabetics and prediabetes categories. Type 2 diabetes states a progressive condition, in which the body becomes resistant to the effects of insulin or gradually fails to produce adequate insulin in the pancreas. In 2017, HI drugs and delivery devices for type 2 diabetes held the largest share in the sector, registering a revenue of $35.1 billion. This was because the prevalence of type 2 diabetes is increasing across the globe with the passing of each day.

Looking at the market growth, the human insulin market players, in order to increase their profits, are joining hands with one another through partnerships and collaborations. For instance, in August 2018, Ypsomed AG entered into a partnership with JRDF. Under the terms of the agreement, JRDF will contribute financial resources to help Ypsomed AG ramp up the development of its next-generation, fully-interoperable myLife YpsoPump. Similarly, in October 2018, Koninklijke Philips N.V. (Philips) collaborated with Ypsomed AG to develop digital monitoring services for self-medication adherence, based on Philips’ HealthSuite digital platform and Ypsomed’s connected devices.

Therefore, it is apparent that the steady growth of the market will give players lucrative opportunities to invest in the research and development of improved insulin drugs and delivery systems.